This is the authors' abstract. We don't add key points for this paper.
In our trial, adalimumab was found to be associated with a lower risk of uveitic flare or visual impairment and with more adverse events and serious adverse events than was placebo. (Funded by AbbVie; VISUAL I ClinicalTrials.gov number, NCT01138657 .).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jaffe et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: